^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
HEC68498
i
Other names: CT-365, CT 365, HEC68498, HEC 68498, HEC-68498, CT365
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
HEC Pharm
Drug class:
mTOR inhibitor, PI3K inhibitor
Related drugs:
over1year
Clinical Study of HEC68498 in Patients With Advanced Refractory Solid Tumors (clinicaltrials.gov)
P1, N=12, Completed, Sunshine Lake Pharma Co., Ltd. | Active, not recruiting --> Completed
Trial completion
|
HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog)
|
HER-2 negative • PIK3CA mutation • PTEN mutation
|
HEC68498
almost2years
Clinical Study of HEC68498 in Patients With Advanced Refractory Solid Tumors (clinicaltrials.gov)
P1, N=12, Active, not recruiting, Sunshine Lake Pharma Co., Ltd. | Recruiting --> Active, not recruiting | N=72 --> 12 | Trial completion date: Oct 2021 --> Dec 2022 | Trial primary completion date: Feb 2021 --> Jun 2022
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog)
|
HER-2 negative • PIK3CA mutation • PTEN mutation
|
HEC68498
4years
Clinical Study of HEC68498 in Patients With Advanced Refractory Solid Tumors (clinicaltrials.gov)
P1, N=72, Recruiting, Sunshine Lake Pharma Co., Ltd.
Clinical • New P1 trial
|
HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog)
|
HER-2 negative • PIK3CA mutation • PTEN mutation
|
HEC68498
Share via
